Dabigatran is the newest generation of oral anticoagulant drugs – direct thrombin inhibitors (DTIs), belonging to non-peptide thrombin inhibitors and instead specifically and selectively blocks the thrombin activity (free or bound) to prevent coagulation.
*The following content is generated by AI and is for reference only.
Overview
Dabigatran etexilate is a prodrug of the direct thrombin inhibitor dabigatran, widely used in anticoagulant therapy. Its core synthesis involves esterification and purification processes to ensure high purity. Molecular formula: C22H28N6O5; CAS No.: 254107-91-8.
Application
- Pharmaceutical manufacturing for stroke prevention in atrial fibrillation.
- Blood coagulation research and development in clinical trials.
- Production of generic oral anticoagulant formulations.
Precautions
Strictly contraindicated in patients with active bleeding or severe renal impairment. Storage requires cool, dry conditions below 25°C to maintain chemical stability and prevent hydrolysis.